The profit margin of Australia's medical and pharmaceutical industry has declined, and the sales outsourcing of enterprises has become a general trend

Source: People's daily.cn "one time legal price reduction plan" released by the Federal Ministry of health on August 27, 2015 shows that all F1 drugs will face a one-time 5% price reduction As part of the drug benefit program (PBS), the program will take effect on April 1 next year Experts pointed out that as one of the means for pharmaceutical companies to avoid the decline of profit margin, the pharmaceutical contract sales market will usher in a significant growth According to the comprehensive report of Australian media, although the pharmaceutical industry in Australia has been growing steadily in recent years, it also faces many challenges Structural adjustment of several industries, including the drug welfare program launched by the federal government, has seriously affected the pharmaceutical companies in Australia, resulting in a decline in profits A number of large Australian pharmaceutical companies said that in order to control the decline of profit margin, they regarded increasing sales of outsourcing services as one of the main solutions At the same time, an industry analysis and Outlook report released by Capgemini management consulting company shows that from 2008 to 2015, the contract sales market scale in the local pharmaceutical industry will see a 12.2% increase According to the latest Australian Pharmaceutical Industry Report data released by PwC, 42% of Australian pharmaceutical companies said they would slow down the process of submitting new drugs under the influence of the drug welfare program According to the report, drug welfare programs lead to inefficiency, increased uncertainty and loss of confidence in the pharmaceutical industry As early as 2008, another report published by the company also showed that the return on drug R & D investment of Australian pharmaceutical companies was gradually declining Dr George syrmaris, chief executive of the IQ group global in Australia, said there were many other factors contributing to the decline in profits in the pharmaceutical industry, including the lack of innovative medicine, the decline in revenue due to the expiration of existing pharmaceutical patents, and the market share of generic drugs He believes that many pharmaceutical companies will balance falling profit margins by reducing operating costs, which was also reflected in an earlier report issued by Capgemini consulting It is understood that the decline in profit margin of the pharmaceutical industry is not a unique industry phenomenon in Australia A survey conducted by Ames in May last year found that the global pharmaceutical industry needs to save 36 billion US dollars to maintain the current profit margin of 25.7% in 2017, while 58% of pharmaceutical companies believe that increasing sales outsourcing services is one of the main solutions to the decline of profit margin European strategic consulting company also believes that there is a clear trend for pharmaceutical companies to increase their sales outsourcing services Many companies subcontract 20-30% of their sales and marketing businesses to contract sales companies Dr semaris believes that more and more Australian pharmaceutical companies will adopt this approach to reduce sales and marketing expenses In the next few years, Australia's pharmaceutical sales outsourcing services will show a double-digit growth trend According to him, the total contract sales market value of the pharmaceutical industry in 2009 was $3.7 billion, which will rise to $9.2 billion next year He said that in Australia, the potential of the pharmaceutical contract sales market is huge but has not been developed The establishment of farmaforce under IQ international group seizes this global growth opportunity and fills the market gap in Australia As the only contract sales enterprise in Australia that uses independent third-party data to analyze its sales performance, farmaforce is applying for global quality management system certification to stabilize its core competitiveness in the industry Farmaforce will be listed on the Australian Stock Exchange in September this year The company plans to issue 20 million shares of common stock through IPO at a price of $0.3 per share, in order to become the first listed company in the contract sales industry in Australia.